Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has been given a consensus recommendation of “Hold” by the ten ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $6.00.
Several brokerages have recently commented on OMED. SunTrust Banks reiterated a “hold” rating and set a $4.00 price target on shares of Oncomed Pharmaceuticals in a research report on Friday, October 6th. Zacks Investment Research cut shares of Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Cantor Fitzgerald set a $6.00 price objective on shares of Oncomed Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, January 4th.
Oncomed Pharmaceuticals (NASDAQ OMED) opened at $2.32 on Friday. Oncomed Pharmaceuticals has a fifty-two week low of $2.30 and a fifty-two week high of $10.89. The firm has a market capitalization of $91.61, a PE ratio of -1.23 and a beta of 2.24.
WARNING: “Oncomed Pharmaceuticals Inc (OMED) Receives Average Recommendation of “Hold” from Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/03/oncomed-pharmaceuticals-inc-omed-receives-average-recommendation-of-hold-from-analysts.html.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.